ResearcherFirst Affiliated Hospital of Nanchang UniversityNo recent work listed

Mei Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4656-3752; OpenAlex author ID A5060503081. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper

Papers 1

Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via the cAMP-CREB axis. Last author DOI 10.1007/s12672-023-00626-1 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Weidan Fang · 1 shared paper, 2023 · strength 0.22
- Paper Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via… DOI 10.1007/s12672-023-00626-1 ↗
Xin Yu · 1 shared paper, 2023 · strength 0.22
- Paper Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via… DOI 10.1007/s12672-023-00626-1 ↗
Jianping Xiong · 1 shared paper, 2023 · strength 0.22
- Paper Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via… DOI 10.1007/s12672-023-00626-1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.